162 related articles for article (PubMed ID: 34592353)
21. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition.
Findeisen HM; Gizard F; Zhao Y; Qing H; Heywood EB; Jones KL; Cohn D; Bruemmer D
Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):851-60. PubMed ID: 21233448
[TBL] [Abstract][Full Text] [Related]
22. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D
Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756
[TBL] [Abstract][Full Text] [Related]
23. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
24. Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
Jang YG; Hwang KA; Choi KC
Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453545
[TBL] [Abstract][Full Text] [Related]
25. Formation of AR-SMRT binding in prostate cancer cells treated with natural histone deacetylase inhibitor.
Trtková K; Pašková L; Matiješčuková N; Kolář Z
Cancer Biomark; 2010; 7(2):79-90. PubMed ID: 21178266
[TBL] [Abstract][Full Text] [Related]
26. Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.
Xu Q; Liu X; Zhu S; Hu X; Niu H; Zhang X; Zhu D; Nesa EU; Tian K; Yuan H
J Cell Mol Med; 2018 Mar; 22(3):1909-1922. PubMed ID: 29327812
[TBL] [Abstract][Full Text] [Related]
27. A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.
Patra N; De U; Kim TH; Lee YJ; Ahn MY; Kim ND; Yoon JH; Choi WS; Moon HR; Lee BM; Kim HS
Biomed Pharmacother; 2013 Jun; 67(5):407-15. PubMed ID: 23583193
[TBL] [Abstract][Full Text] [Related]
28. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells.
Phillip CJ; Giardina CK; Bilir B; Cutler DJ; Lai YH; Kucuk O; Moreno CS
BMC Cancer; 2012 Apr; 12():145. PubMed ID: 22494660
[TBL] [Abstract][Full Text] [Related]
29. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
30. HDAC1 and HDAC3 underlie dynamic H3K9 acetylation during embryonic neurogenesis and in schizophrenia-like animals.
Večeřa J; Bártová E; Krejčí J; Legartová S; Komůrková D; Rudá-Kučerová J; Štark T; Dražanová E; Kašpárek T; Šulcová A; Dekker FJ; Szymanski W; Seiser C; Weitzer G; Mechoulam R; Micale V; Kozubek S
J Cell Physiol; 2018 Jan; 233(1):530-548. PubMed ID: 28300292
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells.
Clarke JD; Hsu A; Yu Z; Dashwood RH; Ho E
Mol Nutr Food Res; 2011 Jul; 55(7):999-1009. PubMed ID: 21374800
[TBL] [Abstract][Full Text] [Related]
32. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer.
Ellis L; Ku SY; Ramakrishnan S; Lasorsa E; Azabdaftari G; Godoy A; Pili R
Oncotarget; 2013 Dec; 4(12):2225-36. PubMed ID: 24163230
[TBL] [Abstract][Full Text] [Related]
33. Zyflamend, a polyherbal mixture, down regulates class I and class II histone deacetylases and increases p21 levels in castrate-resistant prostate cancer cells.
Huang EC; Zhao Y; Chen G; Baek SJ; McEntee MF; Minkin S; Biggerstaff JP; Whelan J
BMC Complement Altern Med; 2014 Feb; 14():68. PubMed ID: 24555771
[TBL] [Abstract][Full Text] [Related]
34. Recruitment of HDAC4 by transcription factor YY1 represses HOXB13 to affect cell growth in AR-negative prostate cancers.
Ren G; Zhang G; Dong Z; Liu Z; Li L; Feng Y; Su D; Zhang Y; Huang B; Lu J
Int J Biochem Cell Biol; 2009 May; 41(5):1094-101. PubMed ID: 19013255
[TBL] [Abstract][Full Text] [Related]
35. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer.
Song X; Wang Y; Du H; Fan Y; Yang X; Wang X; Wu X; Luo C
Prostate; 2014 Jul; 74(10):1023-33. PubMed ID: 24811146
[TBL] [Abstract][Full Text] [Related]
37. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
38. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
39. Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses.
El Omari N; Bakrim S; Khalid A; Abdalla AN; Almalki WH; Lee LH; Ardianto C; Ming LC; Bouyahya A
Biomed Pharmacother; 2023 Aug; 164():114886. PubMed ID: 37224752
[TBL] [Abstract][Full Text] [Related]
40. HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer.
Ai J; Wang Y; Dar JA; Liu J; Liu L; Nelson JB; Wang Z
Mol Endocrinol; 2009 Dec; 23(12):1963-72. PubMed ID: 19855091
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
